title: CD59: A long-known complement inhibitor has advanced to a blood group system.
abstract: The blood group system number 35 is based on CD59, a 20-kDa membrane glycoprotein present on a large number of different cells, including erythrocytes. The major function of CD59 is to protect cells from complement attack. CD59 binds to complement components CS and C9 and prevents the polymerization of C9, which is required for the formation of the membrane attack complex (MAC). Other functions of CD59 in cellular immunity are less well defined. CD59 is inserted into the membrane by a glycosylphosphatidylinositol (GPI) anchor. A defect of this anchor causes lack of this protein from the cell membrane, which leads to an enhanced sensitivity towards complement attack. Patients with paroxysmal nocturnal hemoglobinuria (PNH) harbor a varying percentage of red blood cell clones with a defect in GPI-anchored proteins, including CD59. The most characteristic symptoms of this disease are episodes of hemolysis and thromboses. Although CD59 has been classified as a membrane protein for more than 25 years, an alloantibody directed against CD59 was found only recently. So far, the first and sole alloantibody described was detected in a CD59-deficient child. In 2014, CD59 received the status of a blood group system by the International Society for Blood Transfusion Red Cell Immunogenetics and Blood Group Terminology Working Party. Among a variety of almost 20 synonyms, the designation CD59 was chosen for the blood group system and CD59.l for the wild-type protein. The only three alleles published to date are null alleles. All CD59-deficient individuals recognized so far were severely ill, two of whom have died. Most of the reported cases present with a typical clinical picture within the first year of life that includes neuropathy, strokes, and mild Coombs-negative hemolysis. In one published case, the application of the complement inhibitor eculizumab caused a pronounced improvement of the clinical situation.
authors.affiliation: Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Service Baden-Württemberg-Hessen, and University of Ulm, Germany, Helmholtzstr. 10, 89081 Ulm, Germany.
authors.forename: Christof
authors.initials: C
authors.lastname: Weinstock
authors.affiliation: Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Service Baden-Württemberg-Hessen, and University of Ulm, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Anliker
authors.affiliation: Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Service Baden-Württemberg-Hessen, and University of Ulm, Germany.
authors.forename: Inge
authors.initials: I
authors.lastname: von Zabern
mesh_terms: D001789:Blood Group Antigens / Q000737:chemistry* / Q000276:immunology*; D018957:CD59 Antigens / Q000737:chemistry* / Q000276:immunology*; D051056:Complement Inactivating Agents / Q000737:chemistry* / Q000276:immunology*; D006801:Humans
chemical_list: D001789:Blood Group Antigens; D018957:CD59 Antigens; D051056:Complement Inactivating Agents